A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma

British Journal of Cancer

Volumn 82, Issue 12, 2000, Pages 1925-1931

  Eatock, M M ^a   Anthony, D A ^a   El Abassi, M ^b   Wilson, P ^a   Paul, J ^a   Smith, M ^c   Soukop, M ^b   Evans, T R J ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Chemotherapy; Cisplatin; Epirubicin; Gastro oesophageal cancer; Tomudex

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; ESOPHAGUS CANCER; FEMALE; HUMAN; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MORBIDITY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; STOMACH NEOPLASMS; THIOPHENES; TREATMENT OUTCOME;

EID: 0034070549     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Allum WH, Powell DJ, McConkey CC and Fielding JW (1989) Gastric cancer: a 25-year review. Br J Surg 76: 535-540
2. Bajetta E, Di Bartolomeo M, de Braud F, Bozzetti F, Bochicchio AM, Comella P,, Fagnani D, Farina G, Ferroni C and Franchi R (1994) Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. Eur J Cancer 30A: 596-600
3. Bajetta E, Di Bartolomeo M, Carnaghi C, Buzzoni R, Mariani L, Gebbia V, Comella G, Pinotti G, Ianniello G, Schieppati G, Bochicchio AM and Maiorino L (1998) FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. Br J Cancer 77: 1149-1154
4. Beale P, Judson I, Hanwell J, Berry C, Aherne W, Hickish T, Martin P and Walker M (1998) Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol, 42: 71-76
5. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H and Johnston PG (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4: 1469-1474
6. Cervantes A, Villar-Grimalt A, Abad A, Anton-Torres A, Belon J, Dorta J, Tres A, Camps C, Fonseca E and Massuti B (1993) 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 4: 753-757
7. Cheng AL, Yeh KH, Lin JT, Hsu C and Liu MY (1998) Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)-a very effective regimen with good patients' compliance for advanced gastric cancer. Anticancer Res 18: 1267-1272
8. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT and Judson IR (1996) Phase I trial of ZD 1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumours. J Clin Oncol 14: 1495-1503
9. Cunningham D (1998) Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 77: 15-21
10. Elliott TE, Moertel CG, Wieand HS, Hahn RG, Gerstner JB, Tschetter LK and Mailliard JA (1990) A phase II study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer. Cancer 65: 1491-1494
11. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H and et al (1994) A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609-616
12. Fliser D, Bischoff I, Hanses A, Block S, Jocst M, Ritz E and Mutschler E (1999) Renal handling of drugs in the elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharm 55: 205-211
13. Gore ME, Earl HM, Cassidy J, Tattersall M, Mansi J, Seymour L and Azab M (1995) A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol 6: 724-725
14. Highley MS, Parnis FX, Trotter GA, Houston SJ, Penson RT, Harper PG and Mason RC. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. Br J Surg 81: 1763-1765
15. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A and Boyle FT (1995) Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD 1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914-924
16. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 55: 1407-1412
17. Kelland LR, Kimbell R, Hardcastle A, Aherne GW and Jackman AL (1995) Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer 31A: 981-986
18. Kondo K, Murase M, Kodera Y, Akiyama S, Ito K, Yokoyama Y, Takagi H and Shirasaka T (1996) Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 53: 64-67
19. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernandez OA and et al (1991) Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2: 751-754
20. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J Clin Oncol 14: 176-182
21. Meropol NJ, Pazdur R, Vincent M, Willson JK, Kelsen DP and Douglass HO, Jr (1996) Phase II study of ZD 1694 in patients with advanced gastric cancer. Am J Clin Oncol 19: 628-630
22. Metzger R, Leichmann CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B and Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving compbination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316
23. Pazdur R, Meropol NJ, Casper ES, Fuchs C, Douglass HO Jr, Vincent M and Abbruzzese JL (1996) Phase II trial of ZD 1694 (Tomudex) in patients with advanced pancreatic cancer. Investigat New Drugs 13: 355-358
24. Rigg A, Cunningham D, Gore M, Hill M, O'Brien M, Nicolson M, Chang J, Watson M, Norman A, Hill A, Oates J, Moore H and Ross P (1997) A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J Cancer 75: 101-105
25. Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J and Seymour L (1996) A phase II study in advanced breast cancer: ZD 1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 74:479-481
26. Sparano JA, Schwartz EL, Salva KM, Pizzillo MF, Wadler S and Wiernik PH (1990) Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol 13: 374-378
27. Taal BG, Teller FG, ten Bokkel Huinink WW, Boot H, Beijnen JH and Dubbelman R (1994) Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 5: 90-92
28. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A and Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267
29. Yeh KH, Shunm CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC and Cheng AL (1998) High expression of thymidylate synthase is associated with drug resistance of gastric carcinoma to high dose 5-fluorouracil based chemotherapy. Cancer 82: 1626-1631
30. Zaniboni A, Barni S, Labianca R, Marini G, Pancera G, Giaccon G, Piazza E, Signaroldi A, Legnani W and Luporini G (1995) Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer 76: 1694-1699.